pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advance
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
Fibromun, Darleukin
Phase 2 · small molecule · Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.
Fibromun, Darleukin for Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment. is a Phase 2 program (small_molecule) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Philogen S.p.A.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.
- Status
- active
- Trials
- 1